Organon Remeron alpha-2 receptor antagonist antidepressant approved June 14.
Executive Summary
ORGANON REMERON ALPHA-2 RECEPTOR ANTAGONIST ANTIDEPRESSANT is the first in the alpha-2 class to be approved in the U.S. Remeron (mirtazapine) was approved June 14 for treatment of depression. The Akzo Nobel NV pharmaceutical unit Organon reported the submission of NDA 20-415 in April 1994. FDA designated the drug "1S," representing a new chemical entity given standard review by the agency.